NASDAQ$CARM
Carisma Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results for Q4 2023 and provided a business update, prioritizing CT-0525 and restructuring operations.
Carisma Therapeutics reported its Q4 and full year 2023 financial results, highlighting the prioritization of CT-0525 and a restructuring plan to extend its cash runway into Q3 2025. The company is focusing on its ex vivo and in vivo oncology programs, as well as research programs including fibrosis.
- Prioritizing CT-0525 as anti-HER2 CAR-M product candidate and ceasing further development of CT-0508.
- Cash and cash equivalents of $77.6 million as of December 31, 2023, expected to fund operations into the third quarter of 2025.
- Reprioritizing pipeline programs on those with the greatest overall potential and near-term milestones.
- Implemented a restructuring of operations, including pausing development of CT-1119 and a workforce reduction to reduce expenses and streamline operations.
Headline financials
Revenue & EPS history
Carisma Therapeutics · Revenue · Quarterly
$4.29M
Revenue by segment
Carisma Therapeutics · $19.6M total across 1 segment · Q4 2024
- Collaboration Revenues$19.6M—100.0%
Forward guidance
Carisma anticipates that its cash and cash equivalents of $77.6 million as of December 31, 2023, combined with the expected cost savings from implementing the revised operating plan, are sufficient to sustain its planned operations into the third quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q4 2023
+0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+6.2%
Avg return
30 days after
54%
26 / 48 earnings
Positive
+32.8%
Q2 2016
Best reaction
-29.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +6.2% | +10.1% | -98.0% | |
| Q3 2025 | +2.4% | +27.8% | +22.6% | |
| Q2 2025 | -11.8% | -8.6% | +31.7% | |
| Q1 2025 | +3.1% | -1.4% | +153.1% | |
| Q4 2024 | +11.5% | +5.7% | -5.6% | |
| Q3 2024 | -9.0% | -10.4% | -28.0% | |
| Q2 2024 | +10.7% | +26.2% | +25.0% | |
| Q1 2024 | -4.5% | -5.8% | -30.3% | |
| Q4 2023 | -11.5% | -19.8% | -28.2% | |
| Q3 2023 | -19.5% | -11.1% | -15.4% | |
| Q2 2023 | +12.9% | +22.4% | -12.9% | |
| Q1 2023 | -12.3% | -17.7% | +4.1% | |
| Q4 2022 | +1.2% | -9.6% | +62.9% | |
| Q3 2022 | +0.5% | — | — | |
| Q2 2022 | -3.6% | — | — | |
| Q1 2022 | -1.3% | — | — | |
| Q4 2021 | -2.5% | — | — | |
| Q3 2021 | +3.4% | — | — | |
| Q2 2021 | -8.8% | — | — | |
| Q1 2021 | +5.4% | — | — | |
| Q4 2020 | +5.6% | — | — | |
| Q3 2020 | +3.9% | — | — | |
| Q2 2020 | +7.0% | — | — | |
| Q1 2020 | +1.6% | — | — | |
| Q4 2019 | -29.2% | — | — | |
| Q3 2019 | +0.9% | — | — | |
| Q2 2019 | +1.7% | — | — | |
| Q1 2019 | -2.9% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | -7.0% | — | — | |
| Q2 2018 | +2.1% | — | — | |
| Q1 2018 | +17.1% | — | — | |
| Q4 2017 | +19.0% | — | — | |
| Q3 2017 | +2.8% | — | — | |
| Q2 2017 | -12.4% | — | — | |
| Q1 2017 | -2.7% | — | — | |
| Q4 2016 | +13.7% | — | — | |
| Q3 2016 | -4.2% | — | — | |
| Q2 2016 | +32.8% | — | — | |
| Q1 2016 | +6.1% | — | — | |
| Q4 2015 | -8.6% | — | — | |
| Q3 2015 | -0.7% | — | — | |
| Q2 2015 | +15.2% | — | — | |
| Q1 2015 | +17.9% | — | — | |
| Q4 2014 | -2.4% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -3.9% | — | — | |
| Q1 2014 | +1.1% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro